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ABSTRACT 
Our objectives were to measure concentrations of glucose, insulin, insulin-like-growth-factor-
binding-protein-I (lGF BPI) and ~-hydroxybutyrate (BORB) in amniotic fluid (AF), and 
establish if these concentrations were associated with emergence of maternai gestationaI 
diabetes mellitus (GDM). AF samples (n=408) were collected following routine amniocentesis 
(12-22 w,eeks gestation). Glucose and insulin concentrations were elevated in our GDM 
mother-infant pairs, where GDM was associated with a I76g increase in birth weight. Logistic 
regression showed that AF glucose but not insulin was associated with developing GDM. 
Non-linear Bayesian probability plots showed that when 2nd trimester glucose was plotted 
against insulin increases in both were predictive of the subsequent emergence of GDM. In 
conclusion, our findings show that: I) AF glucose but not insulin predicts subsequent 
emergence of GDM and 2) these observed elevations provide evidence that the fetus of GDM 
mothers is being exposed early in-utero to metabolic perturbations (i.e. elevated glucose) that 
may have important long-term metabolic consequences for their future development. 
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SOMMAIRE 
Les objectifs de cette étude étaient de mesurer des concentrations de glucose, d'insuline, 
d'insulin-like-growth-factor-binding-protein-l (lGF BP 1) et (BOHB) dans le liquide 
amniotique (LA), et d'établir si ces concentrations étaient associées avec l'apparition de 
diabète mellitus de gestation (DMG). Des échantillons de LA (n=408) ont été recueillis 
suivant l'amniocentèse de routine (12-22 gestation de semaines). Les concentrations de 
glucose et insuline étaient élevées dans les paires DMG mère-enfants, où le DMG a été 
associé avec une augmentation de 176g du poids à la naissance. La régression logistique a 
démontr~ que le glucose du LA mais pas l'insuline était associée avec le DMG en voie de 
développement. La probabilité non linéaire de Bayesian a montré que dans le graphique 
du glucose du deuxième trimestre en fonction des augmentations d'insuline les deux 
pouvaient prédire l'apparition subséquente de GDM. En conclusion, ces résultats montrent 
que le foetus de mères souffrant de DMG est exposé tôt in utero aux troubles du 
métabolisme qui peuvent avoir des conséquences à long terme et importantes pour leur 
développement futur. 
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I. Overview 
The Western world has experienced an increase in both the incidence and 
prevalence of type 2 diabetes mellitus (DM2) over the last few decades (1). One 
suspected cause of DM2 is being exposed to a diabetic environment in utero, which 
although the pathology is not yet understood, is associated with those offspring having a 
greater risk of subsequently developing DM2 in childhood and early adulthood than 
offspring not exposed to a diabetic environment in utero (2-5). An in utero diabetic 
environment is known to increase the risk for infant morbidity and mortality (6). 
Morbidity in this instance inc1udes abnormal fetal growth (7) and deve10pment (8; 9) as 
well as the increased risk of DM2 in both the mother (10) and fetus (2-5). Specifically, 
infants of GDM pregnancies are at higher risk for macrosomia (6; 10; Il). Other studies 
further postulate that this relationship is independent and over and ab ove that of the 
increased weight ofthe mother (7; 12). 
Currently screening for GDM in the US occurs in mothers at their first prenatal 
visit,. if they are determined to be at high risk, which inc1udes being markedly obese, 
personal history of GDM, glycosuria or strong family history of diabetes. Then they 
undergo glucose testing as soon as feasible. Average risk mothers are generally tested 
between 24-28 weeks of gestation, while low risk mothers do not require testing (13). 
Similarly, in Canada universal screening for GDM is performed in all but those mothers 
determined to be very low risk (lean Caucasian women, < 25 years old, with no personal 
or family history of di ab etes or of giving birth to a macrosomic infant) (14). In Canada, 
screening occurs exc1usively by a two-step oral glucose tolerance test (OGTT) at 24-28 
weeks in which first a 1-hr plasma glucose measurement follows a 50 g glucose load 
(14). At this point, if a normal value is obtained then the mother is determined to not 
have GDM, but if an ab normal result is obtained then a 75 g oral glucose tolerance test 
must follow; an abnormal result will confirm GDM (14). As expected, univers al 
screening for GDM has been shown to be as, if not more effective as the risk factor 
approach in terms of catching more cases of GDM (15), which suggests that under 
diagnosis is likely occurring. 
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CUITent medical interventions are somewhat effective at alleviating the short term 
infant complications associated with GDM (16). Despite this management of short term 
complications, as previously stated, there remains a greater risk for metabolic disorders, 
specificallY DM2 in both mother and fetus of a GDM pregnancy (2-5; 10). Therefore, 
there would seem to be room for improvement in CUITent intervention and treatment 
strategies. Specifically, earlier detection and intervention might he1p alleviate increased 
risk. 
We propose to examine concentrations of glucose, insulin, insulin-like-growth-
factor-binding-protein-l (IGF BPI) and p-hydroxybutyrate (BOHB) in amniotic fluid 
(AF), which bathes the fetus throughout gestation. AF originates from maternaI, 
placental, umbilical, as well as fetal sources; depending on gestational age, its origin will 
vary (17). Amniotic fluid consists of 98% water and is similar to maternaI serum in early 
pregnancy (18). AF protects the infant, prevents mechanical and thermal shock, contains 
nutritional factors, assists in acidlbase balance, and possesses antimicrobial agents (18). 
AF is essential for normal development of the respiratory, gastrointestinal, urinary tracts 
of the fetus as well as its musculoske1etal system (19). Major fetal contributions to the 
composition of the AF inc1ude fetal lungs, trachea, swallowing, and the production of 
urine (20); prior to interfollicular keratinization of skin at 24 weeks (21), sorne ex changes 
of smaller molecules occur directly from fetal blood stream to AF. 
Although concentrations of insulin and glucose have been examined in post-
diagnosis ODM in both serum (22) and AF (23-25), and in diabetic pregnancies (26-29), 
very few studies have directly examined the relationship of AF constituents with impaired 
maternaI glucose tolerance (IGT) during pregnancy or with ODM apriori. A fair number 
of studies have profiled glucose (30-33) (34; 35) and insulin (23; 25) in serum and AF in 
pregnancies with abnormal glycemia. A few studies have examined the re1ationships 
between maternaI diabetes and cord plasma lOF BPI (36); one study found that maternaI 
plasma lGF BPI concentrations that were above a certain leve1 reduced the risk for GDM 
deve10pment (37). Most studies investigating BOHB have been either in vitro (38; 39) or 
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in in utero animal (30; 40) and were designed to elucidate mechanisms, specifically 
elaborating on how elevated plasma BOHB restricts growth in utero and how it serves as 
an adaptation to starvation. Only one study to date has examined in utero AF BOHB 
concentrations fluctuations with maternaI diabetes (31) and none have examined it in 
GDM. 
To date, associations between AF concentrations of glucose, insulin, IGF BPI and 
BOHB and subsequent diagnosis of GDM have never been thoroughly examined. This 
prompted the question as to whether or not concentrations of glucose, insulin, IGF BPI 
and BOHB are perturbed in GDM compared with NON GDM AF (10 weeks prior to 
current diagnosis) and whether any of these could be effective predictors of mothers 
developing GDM. The objectives of this study were 3-fold: 1) to quantify the specific 
effect of development of GDM on offspring birth weight, 2) to measure the 
concentrations of glucose, insulin, IGF BPI and BOHB in a large number of advanced 
age mo~ers' AF and 3) to establish which concentration of AF nutrient in utero of 
glucose, insulin, IGF BPI and BOHB are associated with development of GDM and 
determine specific concentrations of various nutrient combinations that are associated 
with elevated risk of development of maternaI GDM. We simply used mothers who were 
diagnosed with GDM and those who were not (NON GDM) as our classification. 
This thesis is a manuscript-based thesis. It includes a comprehensive review ofthe 
literature, a materials and methods section, followed by a paper submitted to Diabetes 
Care, a general discussion, and bibliography. The appendix includes ethics certificate and 
the consent forms used in the study. 
II. . Gestational Diabetes Mellitus (GDM) 
Gestational diabetes mellitus (GDM) is defined as a temporary condition 
occurring during pregnancy in which hormonal changes and growth demands ofthe fetus 
increase a woman's insulin needs by two to three times in order to maintain normal blood 
sugar co~centrations (41). The first recorded case of diabetes in pregnancy was in 1823 
(42), and information on the detrimental effects ofhyperglycemia during pregnancy on 
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postnatal outcomes emerged beginning in the 1940s and 1950s. The first was 
macrosomia, which is classically defined as an infant born with a birth weight > 4 kg (43; 
44) and this condition in and of itself is associated with increased infant morbidity and 
mortality (45; 46). It was originally believed that this condition was in fact a symptom of 
pregnancy but eventually the term "prediabetes in pregnancy" was coined (42). 
Currently, GDM is defined (47) as 1 hour post 50 g OGTT results in a maternaI blood 
glucose of2: 7.8 mmol/L then a follow up OGTT is required, but if 1 hr value is 2: 10.3 
mmol/L, then diagnosis of GDM is made. If 3 hr 100 g OGTT has 2 of the following 
maternaI blood values: a) FBG 2: 5.3 mmol/L; b) 1 hr 2: 10.0 mmol/L; c) 2 hr 2: 8.6 
mmol/L or d) 3hr 2: 7.8 mmol/L then GDM diagnosis is made. 
The literature illustrates a clear increase in the incidence of GDM over the last 2 
decades in the US (1; 2; 48). It has been shown recently that prevalence of GDM is 
increasing proportionally with the increase in DM2 that has been occurring over time 
within maternaI ethnic groups in the United States (49; 50). Research shows that the 
incidence of GDM in the North American universally-screened population is 3.6% in the 
general population in Victoria in 1996 (11), 7% in the general US population reported by 
the ADA in 2004 (13), and 8 - 18% in the general multi-ethnic Canadian population 
(including aboriginals) as reported in 2003 (14). The increase in both incidence and 
prevalence of GDM is believed to be due, at least in part to the behaviour and lifestyle 
choices by mothers that are creating the existence of more risk factors at the time of 
conception. These risk factors will be discussed in more detail in the following sections 
including maternaI age, prepregnancy body mass index (BMI), and ethnic origin (15; 50; 
51). Both metabolic disorders, GDM and DM2 share many ofthe same risk factors, 
including overweight/obesity and advanced age, certain ethnic groups including Asians 
and Hispanics OS; 50; 51). These risk factors are considered clinically relevant in 
diagnostic protocols as they have all been linked to increased risk for developing GDM 
(10; 13; 14). Therefore, we can consider them as established predictors ofGDM for our 
subpopulation. 
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Currently, there are two methods used to screen mothers in North America for 
GDM. These are: a) univers al screening and b) risk-factor based screening. The former 
screens every mother using an oral glucose tolerance test (50 g glucose load) and the 
latter identifies women who are considered low risk and does not test them at aIl (15). A 
comparison between the two approaches determined that the univers al method catches 
more cases and allows for earlier intervention than the risk-factor method (15). In 
Canada and the United States, risk-factor based screening is used, with sorne differences 
existing between the two countries such as the cut off value for age (i.e. < 25 in US and < 
35 in Canada), and we find screening of most women for gestational diabetes mellitus 
(GDM) uses blood glucose responses to oral glucose tolerance tests between 24-28 weeks 
of gestation (13; 14). Earlier screening occurs only if any two or more identified maternaI 
risk factors exist (13; 14). 
While recent research has also suggested that univers al screening is more likely to 
catch aIl cases of GDM in a population (15), sorne other studies have compared specifie 
testing protocols and determined that sorne are more effective than others at predicting a 
particular outcome (i.e. macrosomia) (52). SpecificaIly, ofthree tests compared in de 
Sereday et al, the 100 g test had lower sensitivity but higher specificity and positive 
predictive value (52). Additionally, there are differences in proto cols used by different 
govemments around the world such as the ADA protocols compared with those used in 
Spain, w~ich would result in sorne countries (i.e. Spain) reporting higher incidence due to 
greater sensitivity of tests (53). It has been suggested that better GDM diagnosis might be 
achieved ifrisk factors are combined with diagnostic tests cut offs (54). Overall, the 
research suggests that a methodology for earlier diagnosis or prediction of risk for 
subsequent GDM diagnosis would be extremely beneficial to the medical community in 
that it would allow for earlier dietary and medical interventions to normalize the in utero 
environment. 
The benefits of such interventions are apparent when one considers the extensive 
literature by Barker on the impact of the in utero environment on the later health of 
offspring (55-60) as weIl that regarding long-term offspring effects ofLGA (3), it would 
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seem that more careful regulation or maintenance of a stable, healthy in utero 
environment should be the prenatal focus. This might decrease the time that the fetus 
may be e~posed to a perturbed metabolic environment in utero and develop 
complications. Interestingly, CUITent oral glucose tolerance testing can be ineffective in 
mothers whose fetus (es) are siphoning glucose at an increased rate (61). 
It has also been shown that infants of diabetic (62-64) and GDM (16; 65) 
pregnancies both have increased risk ofbeing born LGA or with macrosomia. 
A. Determinants of GDM 
The risk factors believed to increase risk for GDM are included in "risk factor 
analysis" performed by both the Canadian (14) and United States (13) governments 
include maternaI overweightlobese, personal history of GDM, CUITent glycosuria or 
strong family history of diabetes. CUITent glycosuria is obviously evidence of 
undiagnosed diabetes and strong family history of diabetes is out of the mother's control, 
therefore, we will not coyer these two in detail. Furthermore, prior GDM is usually 
indicative of existence of the "other risk factors". However, of the other factors, maternaI 
age, prepregnancy BMI and ethnicity (specifically non-Caucasian) were shown to be 
predictive of diagnosis of GDM (49; 66; 67), while only maternaI age and prepregnancy 
BMI were associated with mild gestational hyperglycemia (67). The main determinants 
ofGDM most relevant to this study are described in more detail below. 
1. MaternaI age 
There has also been a recent trend of mother's having children later in Canada, 
the United States and Europe (49; 67-70). This increasing trend has paralleled, to sorne 
extent, the increase in infant birth weight in these countries. Advanced age is a known 
predictor of deve10pment ofhyperglycemia (Le. DM2) (67) and GDM in mothers (13; 14; 
49; 67; 6,9), where advancedage has been shown to be a risk factor for GDM (10; 11; 
51). Specifically, advanced age decreases the pancreas' ability to maintain glucose 
homeostasis like1y due to increased alpha-glucosidase with age (71), which would 
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decrease . the useability of glucose by the tissues and leads to overexpression of the 
SSTR5 gene, which can inhibit pancreatic ceIl's ability to secrete insulin and regulate 
glucose in aging rats (72). In contrast, a recent study detennined that maternaI age has no 
independent impact on infant birth weight (73). MaternaI age has, however, been 
associated with increased rates of primary cesarean sections (74). Interestingly, GDM is 
aiso associated with increased cesarean sections (13; 14; 68). 
2. MaternaI prepregnancy BMI 
A steadily increasing maternaI prepregnancy BMI has been attributed at Ieast in 
part to the increasing trend in infant birth weights between 1978 and 1996 in Canada 
(75). In fact this anthropometric measure has been implicated as a major independent 
predictor of infant birth weight/ fetai growth in both GDM pregnancies (12; 76; 77) and 
non-GDM pregnancies (46; 78; 79). MaternaI overweight and obesity have been shown 
to increase the risk for infant morbidity and mortality independently in GDM pregnancies 
(3; 12; 80). For example, maternaI overweight and obesity increases the risk of infants 
being born c1assified as macrosomic or LGA (46; 78; 79). 
Similarly, maternaI overweight and obesity has aiso been associated with 
development of maternaI gestationai impaired glucose tolerance and gestationai diabetes 
(3; 69; 77; 81). One study suggested that the apparent increase in incidence of GDM is 
independent of maternaI age or ethnicity (48), which suggests, indirectly, that it couid be 
a result of increasing maternaI prepregnancy weight. 
3. MaternaI ethnicity 
Interestingly, in aIl countries where GDM is screened for, the incidence is higher 
in certain ethnicities present in those countries, specifically the (highest to Iowest) 
prevaience seems to be AboriginaIs, Asians, Hispanies then Africans (14; 48; 49; 66; 81; 
82). Generally speaking, maternaI ethnie origin ean inerease the risk of a mother 
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developing GDM because certain ethnicities are at increased risk ofhyperglycemic (67; 
69; 83). Specifically, Hispanie, South or East Asian, African and Aboriginal (Native 
Canadians and Austrailians) are known to be at higher risk for being hyperglycemia (13; 
14; 83). This is believed to be due to the "thrifty gene hypothesis" that suggests that due 
to an evolutionary reaction to repeated famines these ethnicities have become 
increasingly efficient at storing energy and as a result are at higher risk for developing the 
metabolic syndrome and diabetes (84). 
B) Complications 
Interestingly, it has been proposed that pregnancy complications including GDM 
may share the same antecedents as cardiovascular disease (85), which becomes more 
evident in the illustration below (Figure 1) (85). 
Vucular risk 
factors 
~far~« 
~Q~ 
'--------------------------1 ... Age 
+ 
Figure 1. Shows vascular risk factors expressed in middle age, but not clearly identifiable 
in early adulthood, are identifiable during 'excursions' into the "metabolic syndrome of 
pregnancy". Expression ofrisk factors is increased in pregnancies complicated by, for 
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example, pre-eclampsia or gestational diabetes, and associated with increased risk for 
morbidity later in life (85; 86). 
Complications associated with GDM can be divided into two major categories, 
those that affect the mother and those that affect the fetus and can be further divided into 
the short- and long-term for both the mother and the fetus. Our study will focus on those 
affecting the fetus in the short term, since our cohort study finishes at birth. 
1. MaternaI GDM complications 
One of the short term complications for mothers with GDM increased risk for 
preeclampsia (12; 87; 88). Since they both have similar risk factors (i.e. advanced 
maternaI age, obesity) preventative strategies tend to also be similar for both GDM and 
preeclampsia (89). In fact, oIder women have 1.8 times the risk for preeclampsia 
compared with younger controls (73). Overweight and obesity in GDM pregnancy is also 
associated with further increased risk for preeclampsia (12) in addition to being a risk 
factor for GDM. Preeclampsia is associated with elevated risk for infants being born 
premature (90; 91) and therefore in and of itself increases risk for infant morbidity and 
mortality. 
The main long term complication for mothers who experience GDM is the 
evolution ofthis condition into DM2 (4). In fact, GDM is considered an independent risk 
factor fo~ DM2 (88; 92). Most studies have concluded that ~ 15% (93) and 27% (94) of 
GDM pregnancies go on to develop full-blown DM2, and the prevalence of DM2 was 
shown to be three times as high in GDM mothers compared with controls (95), but there 
has been low follow up testing (~14%) (96) and 37% (97) in the GDM post-natal period, 
so it could be higher. Recently, as the definition of the Metabolic Syndrome becomes 
clearer, it has been shown that ~25 % of mothers of GDM pregnancies developed the 
Metabolic Syndrome (98). Interestingly, the incidence of glucose tolerance disorders (i.e. 
DM2, IGT and IFG) was shown to be ~50% in GDM mothers and was lower in those 
treated by dietary intervention only compared with those treated with insulin (99). 
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2. FetallOffspring complications 
i) Fetal growth 
Infant morbidity and mortality is determined in large part by the size of the infant at 
birth, which is determined by its in utero fetai growth rate (79). Birth weight (BW) is one 
of the most telling statistics with respect to determining survivai and health of newborn 
infants in both the developed and developing worlds (100). Genetically, each fetus has a 
programmed height and weight that it should achieve in utero (101). But during gestation 
the fetai growth rate varies based on various regulating factors including characteristics of 
both the pregnancy (i.e. length of gestation) and the mother (i.e. maternaI prepregnancy 
BMI, ethnicity, age and smoking behavior) (102-109). There are a variety of growth rate 
curves currently used in obstetrics practice including the Denver Intrauterine Growth 
Curves (1960-70 in Hispanics), California birth data and US National birth data (110). It 
has been established that the greatest predictor of infant birth weight is gestationai age at 
the time ofbirth (105; 106; 111; 112) and that infant gender definitely has an impact on 
infant birth weight (105; 113) so much so that this has lead to, almost exclusive use of a 
new system for classifying fetai growth that mathematically corrects for gestationai age and 
gender (114; 115). 
Two fetai growth classification systems are now used. The first one is small for 
gestational age (SGA) < 10th percentile, appropriate for gestational age (AGA), between 
10th and 90th percentile, and large for gestational age (LGA» 90th percentiie. The second 
one is: low birth weight (LBW) < 2500 g, and macrosomic > 4000 g, with healthy birth 
weights ly~ng in between these two extremes. It is known that genetically the fetus is 
programmed for a certain growth rate and with a specifie size outcome targeted and that 
certain modifiable factors including characteristics of both the pregnancy (i.e. length of 
gestation) and the mother (i.e. maternaI prepregnancy BMI, ethnicity, age and smoking 
behavior) can limit (116; 117) or exaggerate (45; 76; 118) this genetically predetermined 
growth rate. 
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Three main compartments influence fetal growth in utero: the fetal, placental and 
maternaI. 'For'our purposes, the fetus' influence over its own growth is achieved by 
hormones and growth factors inciuding IGFs and insulin (119; 120). In normal 
pregnancies, hyperinsulinemic fetuses are at greater risk of being born macrosomic, while 
hypoinsulinemic ones are at greater risk of being bom IUGR (121; 122). Additionally, 
placental development affects fetal growth (123). The placenta's main function is as the 
main supply line for fuel and waste exchange between the fetus and mother (124). It is the 
placenta that is thought to be one of the main regulators of the fetal growth rates that 
change with gestation (125). If the placental function is altered for any reason then the 
fetus is deprived of essential nutrients and hormones, as well as causing an accumulation of 
fetal waste products (125). It's commonly known that impairment ofplacental growth and 
development is associated with restricted in utero growth such that often impaired fetal 
growth is associated with decreased placental weight (103). 
Many conditions are known to effect the permeability of the placenta including pre-
eclampsia and hypertension in pregnancy (126; 127) and diabetes (127-129). It has been 
shown that the increased flux of glucose across the placenta (130; 131) is the stimulus for 
the in-utero production of insulin from developing pancreatic islet cells and is the 
precondition for fetal hyperinsulinism in pregnancies complicated by carbohydrate 
intolerance (131) or GDM (130), which in tum leads to increased fetal abdominal 
circumference (132), macrosomia (10; 11; 33; 133-135), body fatness and obesity (132; 
136; 137) and neonatal hypoglycemia (138) and DM2 (4; 137; 139) and GDM (4; 139) in 
the offspring. In fact, there is sorne suggestion that diabetes can increase the permeability 
of the placenta to various nutrients including glucose (129) and insulin (140) therefore 
partially explaining why there is increased risk of macrosomia in diabetic pregnancies (13; 
14; 65; 76; 77; 141; 142). 
a) Macrosomia 
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Macrosomia is classically defined as an infant born with a birth weight > 4 kg 
(43; 44) and this condition in and of itself is associated with increased infant morbidity 
and mortality (45; 46). However, it has recently been established that it is more correct to 
classify infants by their birth weight corrected for their gender and gestational age (114) 
and would be more accurately referred to as LGA (115). Due to the associated risk with 
an infantbeing born under this classification, this condition (i.e. macrosomia/LGA) has 
been used as an outcome in many studies. Pertinent to this study, it was found that 
glucose intolerance during pregnancy (i.e. GDM or pre-existing diabetes) is associated 
with elevated risk of infants being born under this classification (6; 10; 46; 143). Ten 
percent of the world's infants are c1assified as LGA, with most being macrosomic (144). 
In the United States > 100,000 LGA infants are born each year (118), while here in 
Canada the incidence is around 12 % (145). There has been an increase in the prevalence 
of macrosomia (46; 121; 146-148). The increased trend of macrosomia may be 
attributable to both changing maternaI behaviors (75) and increased incidence ofmaternal 
gestational diabetes (121). The changing maternaI behaviors were identified as 
increasing prepregnancy maternaI anthropometrics (i.e. height and weight), parity, 
gestational age, and male births along with decreased smoking and caffeine intake, aIl of 
which increases the risk for delivering an infant that is macrosomic (46). Interestingly, 
the changing maternaI behaviors and characteristics have aiso been associated with 
increased risk for developing GDM (11; 15; 51; 83; 149; 150), which independently 
increases risk for delivering an infant c1assed as LGA or macrosomic (6; 10; 12; 46; 143). 
Infant macrosomia has been associated with several short term complications. 
These inc1ude shoulder dystocia, perinatal asphyxia, protracted labor (121) and increased 
rate of births by cesarian section (45; 121). There is evidence suggesting that 
macrosomic or LGA offspring are at higher risk for metabolic syndrome and DM2 later 
in life (3; 96). The existence of a diabetic in utero enviorment seems to compound the 
complications associated with macrosomia. Specifically, macrosomic offspring from a 
diabetic in utero environment had hypocalcemia, cardiac failure, hypoglycemia, 
hyperbilirubinemia, polycthemia and cerebral edema from asphyxia or trauma in addition 
to the previously mentioned macrosomic complications (121). 
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It has been shown that the accelerated growth associated with LGA starts in the 
second trimester and that current glucose control methods do not seem to have a 'direct 
effect on 'the incidence of LGA infants (151). Interestingly, one potential mechanism for 
this fetal overgrowth may be due to insulin acting to increase the flux of glucose across 
the placenta (152). This is directly dependent on insulin concentrations, which have been 
shown to effect both permeability of the placenta to glucose (153) and placental gene 
expression of insulin transporters (154). The placenta is an essential organ for proper 
fetal development. It acts primarily as a controlled gateway to selectively allow passage 
ofnutrients towards and waste products away from the fetus (155). In fact, in abnormal 
fetal growth conditions, placental function and/or structure is usually altered (39; 155-
157). Interestingly, it has been shown that insulin (along with nitrous oxide) is required 
to activate glucose transport across the placenta (153; 154). Additionally, research has 
shown th,at insulin control over placental gene expression shifts from mother to fetus at 
different times during gestation (154). Furthermore, there is suggestion that the 
permeability of the rat placenta changes throughout gestation such that during key 
periods in development (i.e. organogenesis) insulin is unable to cross the placenta (158), 
which might help explain why blood glucose fluxes across the placenta at an accelerated 
rate in diabetic pregnancies (129; 159) and why with even slight elevations in glucose 
occur during organogenesis, has detrimental consequences to the fetus from abnormal 
organ development to agenesis of a fetal organ (8; 160). 
b) Growth restriction 
In developed countries, around 6% of aIl live births are c1assified as low birth 
weight (LBW) (161). As of 1998, it was determined that the incidence of LBW in 
Canada and the United States had dec1ined modestly over the last several decades (116), 
which he suggests is due to the decrease in intrauterine growth retarded (IUGR) births 
rather thl:ill preterm births. Additionally, the size of term infants has been increasing 
(162). As of 1995, 5.8% of live births were c1assified as LBW (163) and is one of the 
highest risk factors for infant morbidity and mortality both in the short term (164-166) 
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and also, although less obviously, in the long term (55; 58; 167-169). Independent of 
maternaI age, the incidence of LBW was 5.6, 5.5 and 5.7 % in 2000, 2001 and 2002 
respective1y; and for mothers considered of advanced maternaI age (i.e. 35-49 years) was 
6.6, 6.6 and 6.8% in 2000, 2001 and 2002 respective1y (170-172). The rate of small-for-
gestational-age (SGA) infants in Canada was recently determined to be 8% (173). LBW 
is a condition that has complex diagnostic/classification criteria. AlI infants born 
weighing' < 2500 gare classified as LBW according to the World Health Organization 
(WHO) (101; 174). There are 3 categories that define LBW: 1) born before 37 completed 
weeks of gestation and of appropriate-weight-for-gestational age (AGA); 2) growth 
retarded or born before 37 completed weeks of gestation and are small-for-gestational age 
(SGA) and 3) fuIl-Term and growth retarded (174; 175). SGA is considered to be a more 
accurate assessment for predicting at risk birth outcomes due to the fact that it corrects 
for infant gestational age and gender, two very strong and weIl established predictors of 
infant birth weight (115). However, these conditions of fetal growth restriction remain 
more of a concern in pregestational diabetic pregnancies (176). 
A~ mentioned above gestational age is a main predictor of infant birth weight and 
as a result a shortened gestation (i.e. prematurity) is one of the most common causes of 
LBW (177). Another common cause of LBW is intra-uterine growth retardation (IUGR) 
(166). As a result, the two conditions have overlapping risk factors (166) that conclude 
that exposure to a (pre-gestational) diabetic in utero environment is associated with an 
increased risk for IUGRISGA due to substrate (glucose) in availability (137; 176), 
whereas in utero growth in GDM is more commonly associated with elevated risk for 
(and a much higher proportion of) macrosomia/LGA births compared with SGA, which 
is attributed to increased substrate availability and at least adequate insulin (sometimes 
e1evated) (6; 10; 46; 137; 143). However, it is still important to acknowledge that in 
treated GDM pregnancies SGA still occurs as frequently as LGA (142). 
As previously mentioned, one of the short term complications for mothers is that 
GDM increases the risk for preec1ampsia (12; 87; 88; 141). Placental villi lesions are 
commonly present in both IUGR and preec1ampsia (90; 117; 178). Obviously, any 
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structural changes that decrease the surface area available for transfer of nutrients 
between mother and fetus or impair hormonal secretion by the placenta can lead to 
impaired fetal growth (178-180). MaternaI preec1ampsia and pregnancy induced 
hypertension are both known to lead to increased risk for LBW (181). The mechanism 
by which this is believed to occur is via decreased placental perfusion (90; 178). 
ii) Organogenesis in Diabetic Pregnancy 
Most literature on this topic is animal work inducing di ab etes followed by 
measuring tissue concentrations ofkey nutrients often perturbed in diabetes. Specifically, 
they found that elevations in BOHB are often associated with elevated glucose in po orly 
controlled diabetic pregnancy (30; 182) and that brain tissue containing elevated BOHB 
showed decreased cellular growth and differentiation compared with normal animal brain 
tissue su~gesting that high BOHB concentrations during brain development can result in 
smaller brain size and under-developmentldifferentiation of fetal brains (39; 40; 183; 
184). This is supported by the observation that BOHB produced from excess fatty acid 
oxidation acts to limit food intake at the brain (185). 
Other studies have found that renal organogenesis can be impaired, even to the 
point of renal agenesis, in the presence of elevated glucose in diabetic animaIs (8; 160; 
186). One other study found that early proliferation in fetal pancreases between 7 - Il 
weeks of gestation was low and conc1uded that mass differentiation must be responsible 
for increasing the endocrine mass (and capabilities) of the fetus (187). Interestingly, if 
these undifferentiated cells are forced to pump out more insulin early on in gestation, then 
this could result in j3-cell failure earlier in adulthood than if the pancreas was not exposed 
to the diabetic in utero environment and therefore could account for the increased risk for 
DM2 and GDM in offspring from diabetic pregnancies, which may lead to the increased 
occurrence ofDM2, GDM and metabolic syndrome in GDM offspring (3-5). 
iii) Protein glycation 
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The most commonly analyzed fonn of protein glycation in diabetes is one that is 
routinelY,tested to detennine average blood sugar control over the last three months or so 
and is called haemoglobin A1C as shown in figure 2 (from (188». 
Figure 2. The haemoglobin Al C test measures the amount of sugar that becomes 
bound to red blood cells (via haemoglobin) and is an approximation of average glucose 
control over the last 3 months (189). 
Recently, literature has started to investigate by-products of diabetic environments 
collectively referred to as advanced glycation end products (AGEs) (190-201). In vitro 
studies have shown that common proteins inc1uding serum albumin, IgG, collagen and 
hemoglobin can all be readily glycated and result in various AGEs (192; 194; 202; 203). 
When concentrations ofthese AGEs increase proportionately to regular unglycated 
pro teins they can inhibit regular protein functions (196; 204). 
These AGEs could provide mechanistic explanations for the observed effects of 
GDM on fetal development. There have been many studies on AGEs in diabetes that 
have revealed mechanisms to pathologies of several complications associated with 
diabetes inc1uding nephropathy (191; 205), retinopathy (201; 206; 207), nephrothapy 
(192; 208; 209), wound healing (197) and even cardiovascular disease (196; 198; 200; 
210). We can imagine that ifthese same AGEs occurred during organogenesis they could 
inhibit nonnal development. Since, glycation of serum albumin, IgG and hemoglobin 
occurs readily, it would not be surprising that elevated glucose could glycate and inhibit 
function of other proteins known to be important in utero growth regulators, such as 
insulin or IGF BPI. 
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C) AF as a window into the fetal in utero environment 
Amniotic fluid (AF) is known primarily to provide protection for the fetus against 
physicai and thermal shock (211). The complex, constantly changing dynamics of this 
fluid, however, suggest that it has purposes beyond mechanicai and thermal protection 
including a nutrient rich solution that provides the fetus with nutrients (212; 213) and 
functions as a waste receptacle (214; 215). In fact, a recent review underlined the multi-
faceted importance of amniotic fluid to fetai growth and development (211). AF 
originates from both maternaI and fetai sources such that prior to fetai renai development 
(i.e. 8-9 weeks gestation) the majority is from maternaI sources (i.e. trophoblasts, etc ... ) 
and once the kidneys and Iungs are developed the fetus begins to contribute more and 
more to the composition of AF through urination and Iung exudates (211; 216-220). 
Although, the maternaI plasma is the initial source for water content of AF (211), the 
major source of AF in the second trimester is the fetus and includes fetai kidneys (214; 
221; 222), lungs (18; 223) and GI tract (212; 219; 224-228) as weIl as the amniotic cells 
(deciduas) that line the uterus (229). AF is cycled dailyat different rates throughout 
pregnancy mainly depending on the CUITent size of the fetus (212; 224; 225). Prior to 
keritanization of fetai skin (i.e. 24 weeks gestation), there is diffusion of smaller 
molecules into and out of fetai circulation from AF (230). AdditionaIly, as the fetai 
bowel develops, the fetus swallows more AF and, absorb nutrients, then eliminates 
unabsorbed AF through defecation (228). Research has shown that AF contains severai 
different nutrients including carbohydrates, proteins, lipids, vitamin, mineraIs, as weIl as 
various enzymes and immune cells (35; 211). Fetai swallowing is an essenthtl part of 
successfui fetaI development (211) to the extent that impaired fetai swallowing results in 
impaired fetai growth (212; 213; 231; 232). 
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Figure 3. Amniotic fluid pathways illustrating both the nutritional and waste 
receptade roles of amniotic fluid (211). 
SpecificaIly, the fetus is known to swallow AF such that when fetal swallowing 
was prevented by esophagealligation in rabbits, fetal growth was significantly reduced 
and rates ofmorbidity and mortality increased (212; 213). Conversely, AF is known to 
be comprised primarily of fetal fluids including, urine and lung fluid, which suggests that 
as the fetus develops, concentrations of nutrients within AF would increase or decrease 
accordingly. For example, as the fetal kidneys develop and begin to produce larger 
volumes of urine, AF volume increases as do es the concentration of uric acid (215); 
additionally, as the fetallungs mature concentrations of IGF II have been shown to 
increase in AF (233; 234). 
Based on these existing observations, it is easy to understand how amniotic fluid 
may provide us a clinical window into the fetal metabolism. In the next section, we 
explain how glucose, insulin, IGF BPI and BOHB are related to diabetes and GDM. We 
have chosen these constituents because they are aIl quantifiable in AF and their 
concentrations either in blood or AF have, in one way or another, been linked to either 
diabetes or GDM. 
D) AF constituents as biochemical markers of DM2 or GDM 
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1. Glucose 
Glucose is the primary fuel utilized by embryonic cells for energy which in turn 
provides energy for cell growth, division and differentiation of cells, tissues and organs 
(22). It is shuttled across the placenta using active transport down the concentration 
gradient (i.e. mother to fetus) (22; 235). In diabetes, concentrations are high in mother, 
which drives the concentration up and also increases the expression of Glut 1 transporters 
in the placenta (129; 236). The placenta requires energy (237) and insulin (153) on both 
sides to be able to transport glucose effective1y, but is designed primarily to maximize 
delivery of glucose to the fetus (238), which in GDM results in increased glucose delivery 
to the fet~s leading to increased responsive production of insulin by the fetal pancreas 
(61). 
Direct measurements of fetal hyperglycemia are limited but in utero measures of 
AF glucose have been explored as proxies for fetal hyperglycemia such that AF glucose 
concentrations were around 39 ± 13 mg/dl for diabetes groups and 28 ± 5 mg/dl in the 
controls (i.e. not significantly different) around mid gestation (30-33). It has also been 
proposed that sorne women with GDM may experience earlier glucose intolerance (i.e. < 
24 weeks) sufficient to amplify fetal productionlexcretion ofinsulin, which might lead to 
fetal hyperinsulinism (35). By measuring concentrations in three subgroups each sampled 
at different times during gestation (i.e. 13-20,27-34 and 36-42 weeks) (215), a previous 
study revealed that AF glucose concentrations decreased as pregnancy progressed. It is 
believed that these findings were like1y driven by the sharp drop off in AF glucose that 
occurs near term and especially in post-term pregnancies (239). Another study reported 
no difference in mean glucose concentrations between AF ofhydramnios-complicated 
and non-hydrarnnios-complicated AF (i.e. 5.2 ± 2.4 vs. 5.5 ± 2.4) (141). And yet another 
study reported that AF glucose concentrations rose slightly between 14-17 weeks, then 
decreased to the end of pregnancy and concluded that the AF glucose profile reflected the 
maternaI blood glucose that was delivered to the fetus and excreted via the fetal kidneys 
into the AF (240). Finally, another study illustrated an important distinction between 
normal and diabetic pregnancies. Specifically, as normal pregnancies progressed there 
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was an inverse association with AF glucose concentrations, while in diabetic pregnancies 
there was a direct relationship (34). It has also been proposed that sorne wornen with 
GDM rnay experience earlier glucose intolerance sufficient to amplify fetal 
productionlexcretion of insulin leading to fetal hyperinsulinism as a result of earlier 
e1evations in AF glucose (35). 
2. Insulin 
Insulin has been previously quantified in AF. Since direct rneasurernents offetal 
hyperinsulinernia are lirnited, in utero AF insulin rneasured around 17 weeks of gestation 
have been explored as proxies for fetal hyperinsulinernia such that concentrations of 
insulin in AF of rnothers who later developed GDM was found to be higher than those 
who did not (i.e. 0.60 vs. 0.42 !lU/mL) (33; 35; 130; 241).Concentrations that have been 
reported inc1ude 1.21 ± 0.89 mU/L for a study population with 4.6 % GDM prevalence 
where AF insulin concentrations increased by 0.1 rnU/L from 12-24 week (242). This 
study also reported that insulin concentrations were not significantly different in the 
GDM population compared with the non-GDM population (i.e. 1.05 rnU/L vs. 1.0 rnU/L 
respectively) (242). 
There is disagreement regarding sources of AF insulin. Studies suggest that AF 
insulin is of fetal origin and that the increasing AF concentrations observed with gestation 
are sirnply due to increasing production secondary to pancreatic deve10pment (24; 220), 
while there is suggestion that antibody bound insulin may cross the placenta (140). In 
support o.f this, a positive correlation has been shown between maternaI BMI and AF 
insulin levels (242). This study also revealed that insulin leve1s were higher in AF of 
GDM rnothers compared with non-GDM between 12 - 24 weeks of gestation, but these 
differences were attributed to higher maternaI BMI and associated with gestational age at 
tirne of amniocentesis (242). 
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The general developmental profile shows that AF insulin increases between 13 -
25 weeks· of gestation with an average increase of 1.3 - 5.1 /-.lU/mL, while between 27 -
42 weeks of gestation, average increases of 6 - 9.1 ~.lU/mL were reported (243). AF 
insulin values reportedly are elevated to concentrations indicative of individual pathology 
of GDM by gestational week 16-18 weeks (244). Additionally, the study described a 
direct correlation between AF insulin and infant birth weight in fernale infants (244). 
Another study has shown that AF insulin does cross the placental membrane in the forrn 
of (radio-Iabelled) insulin-antibody complex in sorne IDDM pregnancies (140). The 
concentration of animal insulin that was transported across the membrane was correlated 
with infant birth weight (140). 
Prior literature has established that AF in sul in is greater in mothers who gained 
excessive weight during pregnancy compared with those who gained within norrnallimits 
with (245) and without (246) glucose infusion, providing evidence that AF insulinl fetal 
insulin response is influenced by maternaI weight gain. Another study found a negative 
correlation between insulin and APGAR score of newborns at both one and five minutes, 
although no correction for potential confounders occurred (29). Finally, another study 
suggested that the difference between concentrations of AF insulin measured in the third 
trimester was due to exaggerated fetal f3-cell activity (i.e. as a source of insulin over-
production) (247), which supports previous work on the Pedersen hypothesis (248; 249). 
It has been suggested that AF insulin may be a more sensitive predictor of 
subsequent GDM diagnosis than AF glucose (33). Interestingly, second trimester AF 
insulin has been shown in logistic regression to be associated with later diagnosis of 
GDM when correcting for gestational age and mid-pregnancy weight (35). Moreover, 
elevated AF insulin has been suggested to be indicative of fetal hyperinsulinemia and is 
associatesd with increased incidence ofneonatal hypoglycemia (138). And sorne reports 
have suggested that AF insulin measured as early as 14-20 weeks gestation, rather than 
AF glucose, better predicted the later emergence ofimpaired glucose intolerance (33; 35; 
250) and GDM (130). Interestingly, diabetes is known to increase the size ofthe 
placenta, which increases the perrneability of the placenta to larger nutrients (251). 
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It is generally believed that an increased flux of glucose across the placenta (130; 
. '131) is the stimulus for the in-utero production of insulin from developing pancreatic islet 
cells and is the precondition for fetal hyperinsulinism in pregnancies complicated by 
carbohydrate intolerance (131) or GDM (130). This increased AF insulin concentration 
in tum leads to increased fetal abdominal circumference (132), macrosomia (10; 11; 33; 
133-135), body fatness and obesity (132; 136; 137) and neonatal hypoglycemia (138) and 
type 2 diabetes (4; 137; 139) and GDM (4; 139) in the offspring. 
3. Insulin-like-growth-factor-binding-protein-l 
IGF BPI has been previously quantified in AF. In fact, several studies have identified 
this protein as the most abundant of the IGF BPs in AF (252; 253). Reportedly, its 
concentration in AF increases 20-fold (1.6 ± 0.3 to 33.0 ± O.lng/mL) from 9 - 12 weeks 
of gestation (254) and has further been shown to increase between 14 - 20 weeks of 
gestation (253). Another study reported that AF IGF BPI concentrations increased 
rapidly from 9 - 20 and again from 36 - 42 weeks of gestation (255). The peak levels 
during gestation were observed to occur at 16 weeks (i.e. median 145.2 mg/L) (255). 
This IGFaxis is known to be an important regulator offetal growth and 
development (256-259). Several ofthe IGF and their binding proteins have been 
identified in AF (260; 261), and prior studies have shown that relationships do exist 
between AF IGF, their binding proteins and fetal growth and development (27; 120; 252; 
253). Specifically, we found a negative relationship between AF IGF BPI and infant 
birth weight in exc1usively non-GDM infants (252), while another study reported that 
lower IGFI was associated with IUGR (120). One other study showed that elevated AF 
IGF BPI was associated with decreased placental size rather than birth weight (253). 
ANother study conc1uded that AF IGFI was higher in diabetic pregnancy and in infants 
bom with higher weights (27). 
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IGF BPI is a protein that primarily transports and stores IGF 1 and II (262), both 
ofwhich carry out their actions in the first half ofpregnancy compared with insulin that is 
the primary growth factor of the second half ofpregnancy (43). A recent study revealed 
that amniotic fluid IGF BPI is produced almost exc1usively from maternaI sources (229). 
Its concentration is known to increase with gestation and correlate with IGF 1 and lOF II 
concentrations in AF (253), peaking around 16 weeks (255). Recent literature has 
revealed that cord serum highly phosphorylated IGF BPI was lower in GDM fetuses 
compared with controls (36), which suggests that these decreased levels ofhigh affinity 
IGF BPI, which is inhihitory to IGF-action (263; 264), may he partiaHy responsihle for 
the increased growth observed in ODM. 
Research has found that expression of IGF BPI in rat liver tissue is completely 
inhihited .by insulin (265), which is known to he the primary regulator in the non-pregnant 
state (266). This relationship was found to he altered in preec1ampsia such that the 
inverse relationship observed throughout pregnancy in non-preec1ampsia changed to a 
positive one after 24 weeks in preec1ampsia (266). Further, it has been shown that in 
human serum, proinsulin was a significant predictor of serum IGF BP 1 concentrations in 
obese children (267), serum IGF BPI is inversely correlated with insulin in adult men 
(268). Interestingly, a study in non-pregnant adults revealed that IGF BPI concentrations 
differed across three specific ethnic origins and these changes were found to be linked to 
differing diet composition (269). One study examined Asian pregnancies and found that 
in maternaI serum, IGF BPI concentrations were inversely associated with glucose 
concentrations at 0, 1 and 2 h post glucose load in oral glucose tolerance tests in the third 
trimester~ while in the second trimester maternaI serum IGF BPI was inversely correlated 
with mother's own weight and aH fetal anthropometric measures inc1uding estimated 
weight, subcutaneous fat and growth of abdominal circumference (270). 
4. ~-Hydroxybutyrate (BOHB) 
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Diabetes causes the inability of ceUs to take up and subsequently use glucose as 
fuel. As a result, tissues including the fetus have to adapt to other fuels that are useable in 
the presence ofthis condition (22). One fuel known to be both necessary (39) and 
potentially teratogenic (30; 31; 38; 271-273) to the fetus is BORB. BORB has been 
identified in AF (274). Pregnant women with ketonuria experience more 
oligohydramnios and intrauterine growth retardation (275). Because increased delivery 
of f3-hydroxybutyric acid in pregnant sheep lowered P02 and elevated fetallactate (271), 
researchers have suggested that fetal oxygenation during hyperketonemia is reduced. 
In the scientific literature, ketones bodies have been related both to fetal growth 
(39; 272;'276) and to fetal distress particularly decreased brain weights secondary to 
maternaI starvation or diabetes (40; 273) Inhibition of pyrimidine synthesis (273) has 
been suggested as one ofthe main teratogenic roles for elevated BORB during pregnancy. 
This decrease in brain pyrimidine synthesis is considered the mechanism by which the 
fetus decreases its metabolic demands to conserve energy in the face of maternaI 
nutrition~l deprivation. 
Very little information exists on AF BORB concentrations and essentially none 
for this time :frame that we're observing. Previously reported concentrations of AF 
BORB include a study in pregnant ewes that found during maternaI ketonemia BORB 
was transferred across the placenta and and metabolically effected the fetus specifically 
by decreasing fetal Pa02 and increasing fetallactate concentrations (30; 271). 
It is known that BORB :freely fluxes across the human placenta. Mothers 
undergoing a religious 15-day fast (13 h/day) were sampled and it was found that arterial 
cord BORB correlated with maternaI plasma BORB as well as between maternaI serum 
and venoùs cord BORB concentrations and suggested that BORB concentrations flow 
:freely between the mother and the fetus (277). Although serum BORB was greater in 
fasted compared with non-fasted maternaI plasma, no differences occurred in AF BORB 
with repeated fasting (277). Another study that examined diabetic pregnancies 
discovered that increases in maternaI fasting blood sugar were accompanied by increases 
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in AF glucose and occasionally AF BOHB and further suggest that BOHB freely crosses 
the placenta, since the fetus that is both hyperglycaemic and hyperinsulinemic would not 
be a good source of BOHB (31). 
III. Research questions, hypothesis and specifie objectives 
A) Rationale 
CUITent screening for GDM occurs between 24-28 weeks of gestation and diet and 
insulin therapy are initiated at the point of diagnosis and focus on increasing the 
"tightness" of maternai blood sugar control and regulating fetal growth (142), which is as 
effective as focussing on maternaI glycemic control alone (142) at regulating many of the 
short term complications associated with GDM (278). These complications include infant 
macrosomia, or SGA, as well as maternaI pregnancy induced hypertension and 
preeclampsia. Furthermore, a recent study revealed that current intervention protocols 
seem to help decrease occurrence of adverse birth outcomes including abnormal fetal 
anthropometrics (i.e. macrosomia and SGA) (44; 279). Specifically, Langer compared 
pregnancies that had intervention with those that did not and found the incidence of 
adverse outcome was 59% when women were not treated (i.e. they were not diagnosed 
until> 37 weeks of gestation) compared with 18% when treated with diet and drugs (44), 
while Crowther determined that treating GDM seems to decrease occurrence ofthe more 
serious infant morbidities (i.e. macrosomia and related disorders) (279). Importantly, 
intervention in Crowther's study also included medical intervention at birth (i.e. cesarian 
section) (279). However, despite this "effective" intervention, there is still increased 
incidencè offetal growth abnormalities in GDM infants (6; Il) and an increased risk that 
GDM offspring will deve10p DM2 themse1ves in adulthood. 
This study originated from ongoing work in our labo Specifically, in a previous 
study in our lab, elevations in AF ketones, particularly BOHB, were associated in a post 
priori prabability plots with increased risk ofboth GDM and LGA when combined with 
other metabolic acids (i.e. uric and lactic) and that these e1evations occurred around 10 
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weeks p~or to current diagnosis of GDM at 24-28 wks (280). While this may not seem 
novel, it must be emphasized that these conclusions were based on measurements taken 
using AF, not plasma, collected at 15 wks of gestation. In a study published earlier this 
year (252), we discovered that IGF BPI was inversely associated with infant birth weight 
across all percentile categories in a population from which GDM mothers were excluded. 
This observation supported a previous report that mid-gestational IGF BPI was strongly 
negative1y cOITelated with infant birth weight (281). Our CUITent study pro vides the first 
ever attempt to use AF glucose, insulin, IGF BPI and BOHB concentrations to determine 
a predictive re1ationship with subsequent GDM diagnosis. 
Overall, the research indicates that if earlier diagnosis or prediction of risk for 
subsequeht GDM were possible, it may be extreme1y beneficial to the medical 
community as it would allow for earlier dietary and medical interventions to occur. This 
do es not seem possible using CUITent screening protocols that consider exclusive1y 
maternaI glycemia, since fetuses that already have hyperinsulinemia seem to act as 
buffers to mask their mothers' metabolic perturberbation (61). However, few studies to 
date have attempted to use AF as a window to the fetal metabolic environrnent. If we can 
successfully get a more accurate picture ofthe fetal in utero environrnent present during 
our window, which is the "pre-GDM" period, this may allow for earlier screening and 
detection of perturbations in fetal metabolism. This, in turn, may allow for earlier 
intervention and treatrnent that might decrease the time that the fetus is exposed to this 
perturbe~ metabolic environrnent in utero and therefore could help decrease the incidence 
and risk for short- and long- term complications to both the fetus and the mother. 
Therefore inthis study, we attempt to determine if early elevations of AF glucose, insulin 
and/or BOHB along with a dearth of AF IGF BPI predicts subsequent diagnosis ofGDM. 
B) Hypotheses and Specifie Objectives 
Our hypothesis is that the in utero environrnent as represented by AF insulin, 
glucose, IGF BPI and BOHB would be perturbed, at the time of arnniocentesis, and that 
these earlier AF concentrations could be associated with subsequent risk for development 
ofGDM. 
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Our research questions were: 1) Are AF concentrations of glucose, insulin, IGF 
BPI and BOHB obtained between 15-22 weeks perturbed in pregnancies subsequently 
diagnose~ with GDM at 24-28 weeks compared with those that are not? 2) What is the 
magnitude of the effect in our population that a diagnosis of GD M has on infant birth 
weight? 3) Are any combinations of concentrations of specific AF nutrients and hormones 
associated with increased risk for mothers developing GDM? 
C) Specifie objectives 
Our study goals are fourfold. We want to: 1) describe the prevalence ofGDM in a 
population of older women undergoing routine age-related amniocentesis; 2) show if 
perturbations in amniotic fluid (AF) glucose, insulin or insulin-like-growth-factor binding 
protein (IGF BP) 1 existed at the time ofroutine amniocentesis (range 12-22 wks) in 
those women subsequently diagnosed at 24-28 wks (13; 14; 282) with GDM; 3) use 
multiple regressions in order to: a) establish if an association with these amniotic fluid 
indices and later GDM diagnosis existed; and b) quantify the magnitude of effect that 
subsequent GDM diagnosis has on infant birth weight; and 4) demonstrate, using 
probability maps, specific amniotic fluid concentrations for glucose, insulin and IGF BP 1 
that were predictive of increased risk for GDM. 
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IV. Research Design and Methods 
A) Study design and subjects 
From 1998-2003, pregnant women undergoing age-related amniocentesis for 
genetic testing at St Mary's Hospital Center (Montreal, Canada) were approached to 
participate in this study. Signed consents (n=1300) allowed researchers to collect AF 
samples and to review medical records once genetic testing was completed. Applying 
exclusion criteria (non-singleton births, genetic anomalies, pre-existing diabetes (types 1 
and 2» resulted in 408 mother-infant pairs having infant birth weights, gestational ages 
and gender recorded in the maternaI obstetrics chart at the time of delivery and where 
maternaI GDM status was indicated. McGill's Faculty of Medicine lnstitutional Review 
Board and ethics committees for each of the affiliated hospitals approved aIl procedures. 
Please see appendix 1-3 for the consent form and the ethics for this project. 
Self-reported height, pre-pregnancy weight, age, smoking status (1 =yes, O=no 
(never and quit before pregnancy», gestational age at time of amniocentesis and parity 
were collected; maternaI age, parity, and infant gender, birth weight and gestational age 
were verified from obstetrical medical chart review. Gestational age was uniformly 
calculated based on physicians' estimates using last menstrual period. Ethnicity was 
classified according to literature describing differing pregnancy characteristics by 
ethnicity {283-287) into the following ethnic groupings: Caucasian (North American and 
European), Asian, and other that includes Caribbean and African blacks, Hispanics of 
Mexican, Central and South American descent and those of Middle-Eastern decent. BMl 
was categorized into four groups using National lnstitute ofHealth criteria (288). 
B) Biochemical analyses: 
Amniotic fluid samples, stored at -80c C, were analyzed for glucose, insulin, 
BOHB and lGF BPI. lnsulin (n= 771) was analyzed using the Beckman Access Ultra 
Sensitive Assay System (Brea, California), due to the extreme sensitivity ofthis assay. 
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The Beckman Access uses a one step immunoenzymatic assay that added a monoclonal 
anti-insulin conjugate, an antibody coated paramagnetic particles, and a 
chemiluminescent substrate to the reaction vesse!. It allows insulin to be measured to 
within 0.03-300 f.lIU/L. 
Glucose (n = 585) was analyzed after adapting Abbott Laboratories (North 
Chicago, Illinois) Hexokinase assay kit (No. 6082) for use with a micro plate reader. To 
ensure consistency, comparisons were done between a subset of the same samples that 
were mn on both the Abbott analyzer, which uses the same UV reading absorbance 
wavelength, but requires 75 f.ll of sample, while the microplate adapted kit was able to 
produce consistently the same results but only required 2.5-5 f.ll of sample. 
BOHB analysis was done also using a micro-plate assay derived from Abbott 
analyzer kit (No. 31 O-UV, Abbott Laboratories Diagnostics Division, North Chicago, IL), 
and a similar subset comparison also produced consistent results between the Abbott 
analyzer kit (also requiring 75 f..ll of sample) and the adapted microplate version that 
required only around 20 f.ll of sample. The resulting color change was read at 355 nm 
using a Victor2 plate reader (Wallac Inc, Gaithersburg, MD). 
Fjnally, IGFBPI (n = 637) was analyzed by prepared ELISA kit using Diagnostics 
Systems Laboratories Inc (DSL kit 10-7800, Webster, Texas). This kit measures total 
IGF BPI and was not affected by phosphorylation state. This ELISA consists ofplate 
lined with antibody and enzyme-linked antibodies. It is designed to capture IGF BPI in 
solution and then covers the captured molecules with the enzyme linked antibodies. The 
final steps involve a substrate solution that reacts with the linked enzyme causing a color 
darkening effect. The relative darkening effect is proportionate to the amount of the 
linked enzyme, which directly represents the concentration of total lOF BPI. 
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C) Statistical analyses: 
AIl epidemiologieal data analyses were performed using SAS (Version 9.1, SAS 
Ine., Cary, NC) with P<0.05 set as the minimum for statistieal signifieanee. AIl non-
normally distributed eontinuous data were transformed using square root (AF glucose and 
gestational age at time of amnioeentesis) and logarithmie processing (prepregnaney 
weight, BMI and AF insulin). Bioehemical comparisons between GDM and non-GDM 
mothers inc1uded as eovariates maternaI prepregnancy BMI, age, ethnie origin and 
gestational age at time of amniocentesis (to correct for any potential differences in 
concentrations occurring with gestational age). 
Multiple regressions for GDM diagnosis (logistic) and birth weight (linear) as 
respective dependent variables and with previously established predictors ofbirth weight 
(105) inc1uded in the models. The linear regression was straight forward in that we were 
inc1uding the categorical variable (GDM) as a predictor for infant birth weight while 
correcting for the established predictors ofbirth weight (105). However, the decision 
surrounding how to determine the predictors of our categorical main outcome variable 
(GDM) was more complicated. Specifically, the incidence of our outcome variable 
(GDM) was > 10% and due to the opportunistic nature of our study design (prospective 
cohort), we did not purposely attempt to match cases to controls, all ofwhich suggest that 
we should use a relative risk analysis. Contrarily, the fact that our incidence was close to 
1 0% and that we are inc1uding independent linear variable in our model suggest that 
logistic regression may be more effective. We were able to find a relative risk pro gram 
that ostensibly corrected for linear variables in a relative risk analysis. Therefore, we ran 
both the logistic regression and the relative risk anlaysis. In all analyses, IGF BPI, 
insulin, BOHB and glucose were each inc1uded one-at-a-time. 
In order to develop probability contour maps, AF constituents from both GDM 
and non-GDM mothers were separately modeled using Gaussian mixture modeling which 
optimized the fit of the Gaussian using an expectation maximization (oflog likelihoods) 
procedure employing a quasi-Newton algorithm written in Matlab V6.5 (Mathworks,Inc). 
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A postpriori probability for GDM comparing concentrations of glucose with either AF 
insulin, lGF BPI or BOHB were created using a Bayesian weighting of the Gaussian 
profiles determined from the measured data. A contour map of the probability of 
development ofGDM was then created for variations in insulin, lGF BPI and BOHB as 
related to glucose in the AF (289). 
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V. Section introduction 
The following section of the thesis includes the paper that is to be submitted to the 
Diabetes Care. The candidate chose to prepare this paper and to include it with the thesis 
in lieu of writing a traditional thesis. The amniotic fluid samples were analysed using the 
four assays, two biochemical assays and two ELISA ones. 
Significance was determined at a p-value of 0.05 and was reported as per the 
instructions to authors for Diabetes Care, which is according to the guidelines outlined by 
the International Committee of Medical Journal Editors. For our infant birth weight 
classifications we use the new gender-corrected-birth-weight-for-gestational-age 
(percentile) z-scores (115), which is currently the preferred method by most publications. 
Results tl).at did not attain a 0.05 level of significance but that were relevant to the overall 
understanding to the roles of glucose, insulin and lOF BPI in ODM pregnancies are also 
discussed in the manuscript. 
This manuscript presents only data for AF glucose, insulin and lOF BPI because 
we found BOHB non-significant for aIl tests that we performed. Furthermore, we present 
only the logistic regression data for prediction of ODM due to the fact that its results were 
significant. 
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Abstract 
Objective: We explored whether early elevations in amniotic fluid (AF) glucose and insulin or 
decreases, in Insulin-like-growth-factor-binding-protein-l (IGF BP 1) exist prior to diagnosis of 
GDM and detennined if specifie concentrations of AF constituents were predictive of GDM. 
Research Design and Methods: Consenting mother-infant pairs (n=408) were selected who 
met our inclusion criteria - a singleton pregnancy, no genetic abnormalities and no pre-existing 
diabetes (Type 1 or Type 2) - and for whom sufficient AF sample and appropriate medical 
chart information were available. We compared GDM mothers (n = 52), their infants and their 
AF glucose, insulin and IGF BPI concentrations with non-GDM mothers (n = 356). 
Results: Second trimester AF glucose and insulin concentrations were higher and IGF BPI 
were lower in GDM mothers. GDM was associated with a 176g higher birth weight. Second 
trimester AF glucose, but not insulin, was associated with 1.19 (1.052-1.338) increased risk of 
developing GDM. However, glucose, insulin and IGF BPI were all associated with increased 
risk for GDM when Bayesian probability plots were constructed. 
Conclusions: These results suggest that the fetuses of GDM mothers are exposed early to in-
utero metabolic perturbations that AF glucose may be effective at identi:fying mothers not at 
risk for GDM. 
Key Words: Amniotic fluid, insulin, glucose, IGF BPI and GDM. 
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Introduction 
Currently, gestational diabetes mellitus (GDM) is diagnosed between 24-28 weeks of 
gestation by oral glucose tolerance test (13; 14). Only the presence of other maternaI risk 
factors such as advanced age, elevated prepregnancy weight or BMI, membership in a high 
risk ethnic group, family history of diabetes mellitus, personaI history of impaired glucose 
tolerance and/or prior poor pregnancy outcome indicate earlier screening for GDM (83). 
Amniotic fluid (AF) may provide a window into the fetaI in utero environment. 
Reportedly, AF glucose concentrations are greater in mothers with than those without diabetes 
(29; 290) and in those with GDM than in non GDM mothers (33). AF insulin has also been 
shown to be e1evated in GDM versus non GDM pregnancies (33) and is stronglyassociated 
with macrosomia and birth weight (291). Furthermore, insulin concentrations have been 
associated with subsequent emergence ofGDM (130) and maternaI IGT (35). Additionally, 
one study concluded that AF insulin was a more sensitive predictor of GDM compared with 
AF glucose, but neither were strong enough predictors to be effective screening tools aIone 
(33). No other AF constituent has been associated with subsequent diagnosis ofGDM. 
We hypothesized that: 1) GDM diagnosis would positively predict infant birth 
weight using multiple linear regression; 2) the concentrations of second trimester AF 
glucose, ihsulin may be e1evated and IGF BPI decreased at the time of routine arnniocentesis 
in mothers subsequently diagnosed with GDM; 3) and these AF constituents might predict 
subsequent emergence of GDM. 
Research Design and Methods: 
Study Design and Subjects: 
From 1998-2003, pregnant women undergoing age-re1ated arnniocentesis for 
genetic testing at St Mary's Hospital Center (Montreal, Canada) were approached to 
participate in this study. Signed consents allowed researchers to coHect AF samples and 
to review medical records once genetic testing was completed. Applying exclusion 
criteria (non-singleton births, genetic anomalies, pre-existing diabetes (types 1 and 2)) 
resulted in 408 mother-infant pairs having infant birth weights, gestationai ages and 
gender recorded in the maternaI obstetrics chart at the time of delivery and where 
maternaI GDM status was indicated. McGill's Faculty of Medicine Institutionai Review 
Board and ethics committees for each of the affiliated hospitals approved aH procedures. 
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Self-reported height, pre-pregnancy weight, age, smoking status (1 =yes, O=no 
(never and quit before pregnancy)), gestational age at time of amniocentesis and parity 
were colIected; maternaI age, parity, infant gender, birth weight and gestational age were' 
verified from obstetrical medical chart review. Gestational age was uniformly calculated 
based onphysicians' estimates using last menstrual period. Ethnicity was classified 
according to literature describing differing pregnancy characteristics by ethnicity (285-
287) into the folIowing ethnic groupings: Caucasian (North American and European), 
Asian, and other that includes Caribbean and African blacks, Hispanics of Mexican, 
Central and South American descent and those of Middle-Eastern decent. BMI was 
categorized into four groups using National Institute of Health criteria (288), so that we 
could separate out the overweight and obese. These groups include < 18.5 kglm2, 18.5-
24.9 kglm2, 24.9-29.9 kglm2 and ~ 30 kglm2• 
Biochemical Analyses: 
Amniotic fluid samples, stored at -80°C, were analyzed for glucose, insulin and 
IGF BPI. Insulin was analyzed using the Beckman Access Ultra Sensitive Assay System 
(Brea, California), a one step immunoenzymatic assay that added a monoclonal anti-
insulin conjugate, an antibody coated paramagnetic particles, and a chemiluminescent 
substrate to the reaetion vessel. Insulin was measured to within 0.03-300 j.lIU/L. Glucose 
was analyzed after adapting Abbott Laboratories (North Chicago, Illinois) Hexokinase 
assay kit (No. 6082) for use with a micro plate reader and IGFBPI by ELISA using 
Diagnostics Systems Laboratories Ine (DSL kit 10-7800, Webster, Texas), which 
measures total IGF BPI and is not affected by phosphorylation state. 
Statistical Analyses: 
AlI data analyses were performed using SAS (Version 9.1, SAS Inc., Cary, NC) 
with P<0.05 set as the minimum for statistieal significance. AlI non-normalIy distributed 
eontinuol:ls data were transformed using square root (AF glucose and gestational age at 
time of amnioeentesis) and logarithmie proeessing (prepregnaney weight, BMI and AF 
insulin). Analyses ofbioehemieal eompounds between GDM and non-GDM mothers 
included eovariates maternaI prepregnaney BMI, age, ethnie origin and gestationai age at 
time of amnioeentesis. Multiple regression was ron for GDM diagnosis (logistic) and 
birth weight (linear) as respective dependent variables and with previously established 
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predictors ofbirth weight (105) and GDM (13; 14) inc1uded in the models. IGF BPI, 
insulin and glucose were included one-at-a-time in separate regression models. In order to 
develop probability plots, AF constituents from both GDM and non-GDM mothers were 
separately modeled using Gaussian mixture modeling which optimized the fit of the 
Gaussian using an expectation maximization (of log likelihoods) procedure employing a 
quasi-Newton algorithm written in Matlab V6.5 (Mathworks, Inc). A postpriori 
probability for GDM comparing concentrations of glucose with either AF insulin or IGF 
BPI were created using a Bayesian weighting of the Gaussian profiles determined from 
the measured data. A contour map of the probability of development of GDM was then 
created for variations in insulin and IGF BPI as related to glucose in the AF (289). 
Following the probability plots, we evaluated specificity (true negatives/ total negatives) 
and sensitivity (true positives/ total positives) and accuracy. Specificity was cac1uated as 
number oftrue negatives/ number oftrue negatives + false positives (292). Sensitivity 
was cac1uated as number of true positives / number of true positives + number of false 
negatives (292). Accuracy was calculated as number oftrue correct predictions / total 
number of individuals. 
Results: 
Mothers were older (37.9 ± 0.12 yrs), normal weight (23.8 ± 0.23 kg/m2), non-
smoking (87%) and multi-ethnic (64% Caucasian, 20% Asian and 16% Black, Middle-Eastern 
and Hispanic combined. Infants were born at nonnal weight with a mean birth weight of3462 
± 22 g and an AGA percentile ranking of53.3 ± 1.3 %, at term (39.5 ± 0.07 wks). Our 
concentrations of AF glucose, insulin and IGF BPI were 4.07 ± 0.12 mmollL, 0.61 ± 0.02 
pmol/L and 34360 ± 1448 ng/ml respectively. 
Orthe AF constituents obtained between 12 - 23 weeks of gestation, insulin and IGF 
BPI differed across these gestationaI ages (data not shown). SpecificaIly, AF insulin 
concentrations were higher after 16.5 weeks compared with ~ 15.5 weeks as were AF IGF 
BPl,which was higher after 15.5 weeks versus earlier time points. In contrast, AF glucose 
concentrations did not differ across the gestational ages at time of arnniocentesis. 
MaternaI and infant characteristics differed between GDM and non-GDM mothers and 
their infants (fable 1). GDM mothers were shorter, heavier, and had a mean BMI c1assified 
as overweight (26.3 ± 1.0 kg/m2), the proportion of GDM mothers vs. non GDM mothers who 
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were oveiweight was 36.5% vs. 19% and for obese 21 % vs. 7.3%, respectively. More Asian 
mothers were diagnosed with GDM (46% vs. 16%). Even though our study was conducted in 
advanced aged mothers (i.e. 37.9 ± 0.12 yrs), our GDM mothers were still older (38.7 yrs) vs. 
37.8 yrs for our non-GDM mothers. Infants born from GDM mothers were heavier (3510 g 
vs. 3445g), with higher gender-corrected-birth-weight-for-gestationaI-age percentile ranking 
(64.8 ± 3.7 % vs. 51.6 ± 1.4 %). Markedlymore GDM infants were born LGA (21% vs. 7%) 
and GDM infants were born slightly earlier than their non-GDM counterparts (39.0 ± 0.21 
weeks vs. 39.6 ± 0.07 weeks). 
The in utero environment was characterized by measurements of three AF 
constituents: glucose, insulin and IGF BPI. AF from our GDM mothers had higher 
concentrations of glucose and insulin and Iower concentrations of IGF BP 1. Inclusion of 
covariates (maternaI BMI, age, ethnicity, smoking behavior, infant gender and gestational age 
at the time of amniocentesis) did not affect the observed elevations of AF glucose, insulin, but 
did remove the significance of the decreased concentration ofIGF BPI observed in GDM. 
With covariates (maternaI BMI, age, ethnicity, smoking behavior, infant gender and 
gestation<!1 age at the time of amniocentesis) entered one at a time we were able to demonstrate 
that maternaI age and ethnicity accounted for much of the observed difference in AF IGF BPI 
concentrations between GDM and non-GDM moms. 
Multivariate linear regression analysis for infant birth weight that corrected for 
established predictors of infant birth weight including maternaI prepregnancy weight, height, 
smoking behavior, infant gender and gestational age determined that GDM was associated 
with a 176g increase in birth weight (Table 2). This model accounted for 31.6 % of the 
variability in infant birth weight in our population. 
Multivariate Iogistic regression for subsequent diagnosis of GDM reveaIed that 
maternaI BMI, age, ethnic origin and increased second trimester AF glucose concentrations 
were a11 associated with increased odds ofmothers developing GDM (i.e. 10 %,16.4 %,81.1 
% and 18:6 % respective1y) (Table 3). Neither AF insulin nor IGF BPI were significant 
independent predictors when included one-at-a-time in place of glucose in a model where we 
controlled for gestational age at the time of amniocentesis for the insulin and IGF BPI modeIs, 
sincethese concentrations were found to differ by gestationaI age at the time that they were 
sampled (i.e. amniocentesis). 
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Bayesian posterior probability contour maps were created to assess risk for subsequent 
GDM diagnosis based on combinations of AF constituent concentrations (Figure lA-B). 
Specifically, lower concentrations of AF lGF BPI «3 ng/ml) concentrations in combination 
with higher AF glucose (>7.5 mmollL) were associated with >70% risk ofmothers being 
subsequently diagnosed with GDM. Alternatively, high AF insulin (> 1.5 pmollL) 
concentrations in combination with high AF glucose (>7.5 mmol/L) were associated with 
>80% risk for mothers being subsequently diagnosed with GDM. The highest accuracy for 
our insulin vs. glucose probability plot was 68%. With this tool, we were better able to mIe 
out the disease (i.e. specificity = 74%) than to identify it (i.e. sensitivity = 27%), thus we could 
more accurately classify non-GDM mothers using concentration combinations of each of these 
2 AF constituents with AF glucose compared with GDM mothers. Our lGF BPI vs. glucose 
probability plot had an accuracy of 64% with a specificity of 68% and a sensitivity of 3 8%. 
Conclusions: 
O~ study resulted in four major findings including: 1) early 2nd trimester AF glucose 
and insulin concentrations were elevated while lGF BPI was decreased in mothers 
subsequently diagnosed with GDM; 2) the magnitude of the effect of diagnosis of GDM on 
infant birth weight while correcting for previously established predictors of infant birth weight 
was 173 grams; 3) early 2nd trimester AF glucose was associated with increased odds of 
mothers developing GDM; 4) Bayesian posterior probability plots of our 2nd trimester AF 
concentrations associated both lower IGF BPI and increased insulin in combination with 
increased glucose with > 80% risk for mothers developing GDM. 
GLUCOSE 
Our study showed that AF glucose was already elevated in our GDM population by 15 
wks gestation. Sorne studies have suggested that glucose passes freely across the placental 
barrier vià facilitated diffusion (293). One study actually showed that AF glucose was not 
associated with fetal hyperinsulinism prior to 23 wks gestation (240). Developmental profile 
shows that AF glucose decreases as gestation progresses; therefore it is not surprising that our 
glucose values are higher compared with those measured by Weiss et al at 38 weeks. Other 
differences were negligible. We showed that AF glucose was elevated in mothers 
subsequently diagnosed with GDM and that AF glucose increased the odds that a mother 
would develop GDM even when we controlled for appropriate confounders. Specifically, a 1 
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mmol/L increase in AF glucose by 15 weeks of gestation was associated with an odds ratio of 
1.19 that amotherwould develop GDM. Furthermore, construction of2 Bayesianprobability 
maps revealed AF glucose as à consistent predictor of GDM as both plots showed non-linear 
risk profiles. The elevations in AF glucose required for> 80% risk of mothers developing 
GDM were biologically plausible in our population and occurred in 1.5% of mothers. We 
believe this early elevation in AF glucose has the potential to be problematic for the 
developing fetus, since exposure to elevated glucose has been shown to glycate exposed 
organs, proteins and enzymes, in various models (208; 294). Additionally, this increased 
glucose load could also alter the development of the developing fetal pancreas (187), thus 
potentially leading to an underdeveloped or malformed organ or accelerating the exhaustion of 
~ cells, both of which might at least partially explain why GDM offspring are at higher risk for 
type 2 diabetes and GDM during adulthood (4; 5). 
INSULIN 
It has been previously suggested that AF insulin may be a better predictor than AF 
glucose of IGT (33). Our insulin measures were lower from those previously reported by Star 
et al, Carpenter et al and Buhling et al, likely due to the use of the newer ultra-sensitive assay, 
which is currently accepted as the gold standard. Our study revealed that AF insulin was 
elevated in our GDM mothers, but did not predict GDM when correcting for maternal age, 
BMI, ethnicity and gestational age at the time of amniocentesis. Importantly, however, 
Bayesian probability mapping found that combinations of elevated AF insulin in combination 
with elevated glucose increased the risk for mothers developing GDM. Importantly, an 
elevation of 1.5 pmol/L in AF insulin increased by >80% the probability for mothers 
developing GDM. 4.6% of our mothers who developed GDM had AF insulin ofthis 
magnitude. Interestingly, we found that AF insulin concentrations were correlated with 
maternal BMI (t=0.24065, p=<O.OOOl). Prior studies have shown increased placental size to 
be associated with maternaI diabetes (295) and that this increased placental size may result in 
increased fetai size due to increased permeability to maternal substrates and growth factors 
possibly including insulin (295). Therefore, it would seem that second trimester AF insulin is 
not as good a predictor of GDM as AF glucose, but rather its effect is associated with maternaI 
BMI, which tends to be larger in GDM mothers, since larger mothers tend to produce more 
insulin (245). 
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IGFBPI 
Low AF IGF BPI in the presence ofhigh glucose was associated with >80% risk for 
GDM. Interestingly, this decreased concentration ofIGF BPI was biologically plausible in 
our population as 30% of our mothers had AF IGF BP 1 concentrations at this level or lower. 
This finding confirms that the previously reported relationship oflow maternal plasma IGF 
BPI and elevated risk ofGDM (37) also exists for AF. Prior studies have shown that Asians 
are more susceptible to GDM (66; 296) and a few studies have found that ethnicity influences 
IGF BPI such that Asians have lower concentrations of plasma IGF BPI (297). It has also 
been shown that umbilical cord concentrations ofhighlyphosphorylated IGF BPI were lower 
in GDM pregnancies and were inversely correlated to subsequent birth weight (36), so we 
suggest the possibility that this relationship also exists in AF of GDM mothers. Therefore, it 
would seem that AF IGF BPI is not a good predictor ofGDM because Asian mothers account 
for the variance observed. 
There were sorne limitations with this study including fetal weight estimates were 
inconsistently recorded, and various dietary and insulin interventions occurred between the 
time of amniocentesis and birth that were not reported consistently. Undoubtedly, these 
interventions decreased the incidence of macrosomia. We chose to use z-score growth 
percentiles that have beeen shown to be a more appropriate measure of fetal growth in that 
theyalso account for gestational age and gender (115). 
In conclusion, we showed that AF glucose, insulin and IGF BPI concentrations were 
perturbed by 15 weeks gestation and that these perturbations were associated with emergence 
of GDM, which is also associated with increased infant birth weight. By showing that the 
developing fetus ofGDM mothers is already exposed to a 'diabetogenic risk profile' 10 weeks 
prior to current screening for GDM, our study suggests that this early elevation of AF glucose 
could underscore the elevated occurrence of GDM in GDM offspring later in life. It also 
indicates that earlier screening and intervention may be warranted in order to attenuate long-
term fetal complications. Interestingly, we did find that the classifier that used AF glucose in 
combination with insulin was betler at ruling out GDM than in predicting its occurrence. This 
points to the etio10gy of GDM as multi-factorial. While AF glucose seems to be a good 
potential predictor for GDM, neither insulin nor IGF BP 1 were suitable for pairing with it in 
Bayesian probability plots to effectively predict risk for GDM such that accuracy, sensitivity 
41 
and specificity were maximized. Thus, we suggest the need to examine the earlier exposure of 
the fetus to this "diabetogenic profile" in more detail. 
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Table 1. Comparison of GDM means with non-GDM means l . 
Characteristics NON-GDM GDM p 
Infant 
Birth weight (g) (356) 3445 ± 23 (52) 3581 ± 77 0.0408 
Gender (% male) 54 56 NS 
Gestational age (wk) (356) 39.6 ± 0.07 (52) 39.0 ± 0.21 0.0062 
Birth-weight-for-gestational-age (% ranking) (356) 51.6 ± 1.4 (52) 64.8 ± 3.7 0.0008 
%SGA 4.5 3.8 
%LGA 21.1 
7.0 
% Premature 9.8 17 NS 
MaternaI 
Height (m) (356) 1.62 ± 0.004 (52) 1.60 ± 0.01 0.0136 
Pre-pregnancy weight (kg) (353) 61.9 ± 0.62 (50) 67.5 ± 2.9 0.0231 
BMI (352) 23.4 ± 0.21 (50) 26.3 ± 1.0 <0.0001 
% Overweight 19 36.5 * 
% Obese 7.3 21 * 
Ethnicity 
% Caucasian' 69 35 * 
% Asian 16 46 * 
% Other 15 19 
% Pregnancy-related Hypertension 2.2 1.9 NS 
Smoking(%) 14 12 NS 
Parity (349) 1.1 ± 0.05 (51) 1.4 ± 0.14 NS 
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MaternaI Age (y) 
Amniocentesis week (wk) 
Amniotic Fh.Îid 
Glucose (mmol/L) 
ANCOVA2 
Insulin (pmol/L) 
ANCOVA2 
IGF BPI (ng/mL) 
ANCOVA2 
(348) 37.8 ± 0.13 
(352) 15.1 ± 0.05 
(356) 3.84 ± 0.12 
(356) 0.57 ± 0.02 
(356) 35602 ± 1578 
(47) 38.7 ± 0.32 
(51) 15.3 ± 0.16 
(52) 5.61 ± 0.47 
(52) 0.86 ± 0.13 
(52) 25856 ± 3308 
0.0155 
NS 
<0.0001 
0.0012 
<0.0001 
0.0194 
0.0246 
NS 
1 Data are reported as mean ± sem for characteristics. P < 0.05; 2 ANCOVA - Covariates 
included maternaI BMI, age, ethnicity, smoking behavior, infant gender and gestational 
age al amniocentesis. 
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Table 2. Linear Regression for Infant Birth Weight1• 
Characteristic 
Gestational age (weeks) 
Gender, O=female, 1 =male 
Prepregnancy Weight (kg) 
MaternaI Height (m) 
MaternaI Smoking, O=no, 1 =yes 
Study Population 
(n = 408) 
136 
182 
6.16 
974 
-98 
<0.0001 
<0.0001 
0.0001 
0.0006 
NS (0.0686) 
GD M diagnosis 2, O=no, 1 =yes 176.1 0.0024 
Variability captured (R2 X 100%) 31.65 
1 n=408. P < 0.05. 2 Partial R-sq = 0.0164. 
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Table 3. Logistic regression for GDM1• 
Characteristic 
MaternaI BMI (kg/m2) 
MaternaI Age (years) 
MaternaI Ethnicity 
Amniotic Fluid Glucose (mmoI/L) 
Amniotic Fluid Insulin (pmoI/L) 
Amniotic Fluid IGF BPI (ng/mL) 
OR (CI) 
1.103 (1.034-1.176) 
1.164 (1.019-1.330) 
1.811 (1.225-2.679) 
1.186 (1.052-1.338) 
1.679 (0.915-3.081) 
1.0000 (1.0000-1.0000) 
1 AF constituents were included in separate models one at a time; n=386; All modeIs, 
except glucose, controlled for gestational age at time of amniocentesis; P < 0.05. 
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Figure Legends: 
Figure 1. Figure lA illustrates specifie AF concentration combination ofIGF BPI and 
glucose and the resulting c1ass-conditional Bayesian aposteriori probability density 
plotted as a contour map. Figure lB illustrates specifie AF concentration combination 
of insulin and glucose and the resulting c1ass-conditional Bayesian aposteriori 
probability density plotted as a contour map. 
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VII. General conclusions 
Our multi-ethnic population were mostly healthy with 86.5% not having ever 
smoked; the Canadian population has 81 % non-smokers (145). Our mean BW (3425 g) 
was similar to the Canadian mean BW (3403 g )(171). Our mean gestational age was 39 
weeks, which was comparable with the Canadian mean (172). Furthermore, 6.6% of our 
infants were born SGA, while 12.3% were born LGA; the former is similar to the 
reported mean for developed countries, which was 6% in 2001 (161) and with the 
incidence reported for 2000-2002 for oIder mothers (i.e. 35-49) (170-172), which is 
essentially our study population. However, this was less than the recently quantified 
Canadian mean of 8% (173). This is probably due to the fact that our population is of 
advanced age and that we exc1uded pre-existing diabetes from our study, so we could 
focus on GDM and non-GDM only, as pre-existing diabetes has been shown to increase 
risk for infants to be born SGA (143; 176). Overall, our study population of advanced 
age mothers was similar to the Canadian population except that the mean age of mothers 
giving birth in Canada is 30 yrs (70), whereas our mean age was 38 yrs. Our multi-ethnic 
population had a 12.1 % incidence/prevalence of GDM, which is comparable to a recent 
Canadian multiethnic population report that placed the incidence between 8 - 18% (the 
former not inc1uding and the latter inc1uding aboriginal populations) (14). 
A better explanation of the Bayesian probability plots is given below. Generally, 
Bayes ruIe allows us to determine the probability that X belongs to one group or the other 
--;----
/(c, / C') 
(i.e. Cl or C2). \'~-L~ 
Gaussian mixture modelling is a method of simplifying a data set such that similar 
values ar~ lumped into one Gaussian. Therefore, if there were actually three distinct data 
sets initially, the resulting Gaussian mixture model would have two. The Matlab 
subroutine proceeds in the following manner. First it creates two distinct Gaussian 
mixture models. Then it uses a quasi-Newton algorithm to calculate the Gaussian mixture 
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model expectation maximization. This algorithrn recursively updates distribution of each 
Gaussian model and conditional probability in two steps. The E step computes the 
conditional expectation of the complete log-likelihood and the M step finds the c1uster 
pararneters that maximize the likelihood of the data. Once the expectation has been 
maximized appropriately, the subroutine applies Bayesian decision theory in the forrn of 
Bayes fOrmula (see Figure 5 below). 
Gaussian Mixture Model 
Density p(xlred) Density p(xlyellow) 
1.5 1.5 
0.5 0.5 
Gaussian 
__ ,_ - - - - -;- , " /probabililY 
- ..- - : ___ ~..... ;......... .... .... 1.5 _ .... - 1 
__ -1-- J .......... 1 ~ __ -I-
l -- 1 _.l.. l ",1 1 -- 1 
1 - - 1 1 _-
_-1-- 1 1 _---I-
I 
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5 
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Figure 4. This figure shows both the density and the 3-dimensional representations of 
each ofthe Gaussian distributions created from the GDM (Left Column) and the Non-
GDM (Right Column) populations for the insulin vs. glucose model. 
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Bayesian Analysis of Gestational Diabetes using AF 
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• 
Bayesian Analysis: 
Probability 
OfGDM 
contours P(h 1 D) P(D 1 h)P(h) 
P(D) 
P(h) = prior probability ofwoman 
developing GOM. 
P(O) = prior probability of an AF 
concentration combination existing in 
our training data 0 
P(hIO) = probability of diagnosis of 
GOM given AF concentrations 
(posterior density ) 
P(Olh) = likelihood of concentrations 
given diagnosis of GOM (0 given h). 
Figure 5. This figure shows the Bayesian Contour plot for the insulin vs. glucose model 
and the equation used for calculation of the Bayesian probabilities. 
A) Sam pie Size 
Since this study was a prospective cohort study no power calculation was 
necessary, but rather aIl cases meeting inclusion crieteria were included. This study 
involved collection of 408 amniotic fluid samples from consent-matched mother infant 
pairs. Our GDM subpopulations included 356 non-GDM and 52 GDM subjects; the 
study sample was lowered due to insufficient AF. Specifically, BOHB was the most 
restricted with n=251; insulin, IGF BPI and glucose were aIl equivelant with n=408. 
B) Comparison with literature 
We investigated existing literature on AF nutrients and potential predictive 
relationships with subsequent GDM diagnosis. Among the existing research, three 
constituents of AF are found in relatively large amounts and vary in the in utero 
environments. These include glucose, insulin and IGF BPI, each ofwhich could be 
related to' fetal growth and development as described in the literature review. 
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Our study found that AF glucose was greater in GDM pregnancies compared with 
non-GDM. This finding is comparable to previous studies that found maternaI 2 h post 
prandial glucose to be associated with infant birth weight (298). Interestingly, while 
studies have investigated whether AF glucose can predict infant birth weight in GDM 
(299) and non-GDM pregnancies (299), one study concluded that AF glucose was not 
different in GDM cases compared with controls (33). Our study had a much larger 
sample size (n=408) and our elevations persisted even when we controlled for potential 
confounders including maternaI prepregnancy BMI, age, ethnicity and gestational age at 
the time of amniocentesis. 
We also found that AF insulin was elevated in GDM pregnancies compared with 
non-GD~. Contradiction exists in the literature in that one study concluded that AF 
insulin was not different from controls (242) while another determined that in fact they 
were elevated (33). These studies did not control thoroughly for potential confounders. 
Again, our observed eievation persisted when we statistically controlled for potential 
confounders including maternaI age, BMI, ethnicity and gestational age at the time of 
amniocentesis (13; 14; 48; 300). However, we found that AF insulin was not associated 
with mothers developing GDM. While, prior studies have associated AF insulin 
concentrations with development ofGDM (33; 35). 
Our study aiso found that AF IGF BPI concentrations were lower in GDM 
pregnancies compared with non-GDM. This finding confirms that the previously reported 
relationship oflow maternai plasma IGF BPI and elevated risk ofGDM (37) for AF. This 
difference became non-significant once we corrected for potentiaI confounders of maternai 
ethnicity and age. This has been shown in the literature but not specificaIly for AF or even for 
pregnancy. Prior studies have shown that Asians are more susceptible to GDM (66; 81; 296) 
and a few studies have found that ethnicity influences IGF BPI such that Asian men Were 
found to have lower concentrations ofIGF BPI in theirblood (297). Thus ourresults suggest 
that fuis difference was likely accounted for by the high number of Asians in our GDM 
population (i.e. 46% vs. 16%). We found that AF IGF BP 1 concentrations did not predict 
development of GDM in logistic regression but lower concentrations were associated with 
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elevated risk for development of GDM in combination with AF glucose in Bayesian 
probability plots. This ostensible discrepancy is like1y due to the fact that the logistic 
regression would elucidate mostly linear relationships whereas the Bayesian probability' 
contour maps would reveal non-linear relationships. Previously IGF BPI was inversely 
associated with birth weight (281) even when GDM mothers were excluded (252). Previous 
studies have shown this to be due either to higher leve1s of growth hormone or increased levels 
of circulating IGF 1 (301; 302), which inhibits placental IGF BPI production (303). FinaIly 
umbilicaI cord concentrations ofhighly phosphorylated IGF BP 1, which has the highest 
affinity for insulin-like-growth-factor-I, are lower in GDM pregnancies and were inversely 
correlated to subsequent birth weight (36), so we suggest the possibility that this relationship 
also exists in the AF of Asian mothers. No studies to date have found a relationship between 
maternai age and AF IGF BPI. 
Lastly, we found that AF BOHB concentrations were not different between GDM and 
non-GD:rv:r mothers during our gestationaI time frame (i.e. 12-22 weeks). A previous study 
found that AF BOHB was elevated in GDM pregnancies in the third trimester (31), which was 
later than our study. However, 2nd trimester AF BOHB may not predict development of 
GDM. To our knowledge, no previous literature has explored associations between AF 
BOHB and GDM. Therefore, we present for the tirst time conclusive evidence that AF BOH 
concentrations do not predict development of GDM. However, when plotted against AF 
glucose, AF BOH elevations are associated with an increased Bayesian risk for mothers 
deve10ping GDM, but these e1evations were determined to be biologicaIly implausible in our 
population since none of our mothers had values near or above this. 
Therefore, we provide further evidence that glucose and insulin are e1evated in 2nd 
trimester bf GDM mothers and show for the tirst time that IGF BPI is decreased 
approximately 10 weeks prior to CUITent screening protocols. We also demonstrate that AF 
insulin is the only nutrient that predicts deve10pment of GDM, but that combinations of 
perturbed nutrient concentrations in AF seem to represent a window into fetaI metabolism at 
the time oftheir acquisition and are associated with increased risk for development ofGDM. 
Furthermore, we can postulate that diagnosis of GDM prior to CUITent screening protocols is 
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entirely possible if fetal metabolic indicators are considered instead of maternal, since fetal 
metabolism seems to be perturbed earlier than maternaI. 
C) Methodological effects 
Due to the one-analyte-at-a-time assays that were used in our biochemical 
analysis, the main restriction we faced was that of cost and sample usage. Obviously, 
these are, both partially responsible for the sample number differences that are present 
between our analysed nutrients in this study. The biggest technical sources of error that 
were encountered were the fact that micro-sizing of the glucose assay may have resulted 
in greater variability from the original method that used approximately 30 times the 
volume of AF (i.e. 75 vs. 2.5 J..1I). 
Another important area for consideration is the storage time for the samples. In 
our study, the samples were collected at St. Mary's Hospital and then it was left up to the 
mother to transport them to the Montreal Children's Hospital. Obviously, this time could 
have varied. Previous studies have examined concentration changes in only a few AF 
constituents. Specifically, one study found that concentrations of the enzymes creatinine 
kinase and lactate dehydrogenase were decreased with storage at -20°C, but less so in -
70°C (304). 
The most likely area for error would be during the data management step in which 
the data was exported from the various programs and subsequently imported into MS 
excel. Once in excel, calculations had to be performed on the data dependant on the 
resulting value obtained directly from the analysis (i.e. ab sorbance ). Eventually, the data 
points were converted to units of interest and then copied to the main excel biochemical 
sheet. This step also involved determination of acceptable and unacceptable data points 
and averaging duplicates and triplicates into one useable data point. 
D) Diagnostic Test Efficacy 
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Despite the fact that the probability plots predicted risk for GDM, it would seem 
that biologically all the AF constituent concentrations are plausible, except for AF BOHB 
for which no individuals in the sample population had elevations matching those 
associated with a risk of> 80% (i.e. > 1500 )lmol/L). Interestingly, the insulin and 
glucose GDM classifier (greatest accuracy (i.e. 68.4%) that we generated) had greater 
specificity than sensitivity (i.e. 74.4% and 26.9% respectively), which suggests that our 
diagnostic tool is better at correctly classifying those individuals who do not develop 
GDM as opposed to those who do. 
E) Future Work 
As with any study, there are definitely are as that if modified would make the 
study more applicable to the Canadian population and the findings more acceptable to the 
medical community. Firstly, the fact that this study examines concentrations in frozen 
AF samples is, in and of itself, a limiting factor. Specifically, medical journals that we 
have communicated other findings with have expressed their interest in knowing whether 
or not these findings are valid in unfrozen sampI es. There are few studies that have 
examined the dynamic changes that could occur in AF concentrations of the nutrients 
analysed based on storage time at various temperatures including room and -80 oc. The 
only study that was do ne was over a relatively short period oftime (i.e. 12 hrs or less) and 
found that AF glucose concentration decreased in the presence of infection only (305). 
Expanding the scope of information captured by the maternaI consent forms 
would allow us to determine what associations exist between measured AF nutrients and 
maternaI dietary nutrients and lifestyle habits, which would allow us to then develop a 
more controlled trial in which we could provide a modified diet to mothers with GDM 
and then measure AF nutrients to determine if dietary manipulation directly affects AF 
composition' in GDM as in normal pregnancy (306). This would also allow for any 
confounding effects these nutrients may have on fetal outcomes. For example, it has been 
shown that overall caloric intake is associated directly with infant birth weight (105). 
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MaternaI weight gain is an important variable that we did not have the opportunity 
to examine due to the fact that we do not run the prenatal clinic where the amniocentesis 
is performed. Studies have shown that maternaI weight gain during pregnancy is an 
excellent predictor of infant birth weight (7). Correcting for this statistically or by 
stratification would have allowed us to more accurately identify and control for potential 
confounding effect of maternaI weight gain on the magnitude of the effect of GDM 
diagnosis on infant birth weight. Another area for future examination related to our direct 
involvement in the prenatal clinic is measuring maternaI blood pressure and monitoring of 
this throughout gestation to more accurately account for mothers who develop 
hypertension and its related conditions (i.e. preeclampsia). 
Another beneficial area for future examination is to quantify various glycated 
protein by-products in AF. This would be useful, due to the fact that protein glycation 
may provide a mechanistic explanation for the perturbed concentrations ofIGF BPI (or 
others) in AF (192; 204), since good glycemic control has been shown to decrease 
concentrations of glycated end products in diabetic rat plasma (203). 
To verify that these observations are externally valid, this model needs to be tested 
in data ot:p.er than that we used to generate the mode1. The Gaussian mixture models and 
subsequent Bayesian plots were aIl created from the same data set in which they were 
ultimately tested. 
Lastly, it would be essential ifwe were attempting to catch GDM earlier to 
develop a more comprehensive diagnostic too1. For instance, a multi-dimensional 
Bayesian probability map or a more complex neural network which would interface like a 
PDA into which specific information about the mother's anthropometrics, as weIl as 
categorical variable such as ethnic origin and smoking behavior and, of course AF 
nutrient concentrations. Theses data could then run through an algorithm that would 
pro duce a final Bayesian probability for risk of developing GDM and the c1inician could 
then act àccordingly (i.e. initiate intervention protocols). Of course, the classifier would 
have to be such that it had a high specificity as weIl as an appropriately high selectivity. 
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In conclusion, our study shows that 2nd trimester concentrations of AF glucose, 
insulin and IGF BP 1, but not BOHB are perturbed up to 10 weeks prior to current 
screening and diagnosis of GDM; for every unit (mmol/L) increase in AF glucose 
concentration, there is a subsequent 19% increase in risk for development of GDM in that 
mother, based on the in utero profile; and lastly that AF insulin, IGF BPI and BOHB 
Bayesian concentrations each plotted against AF glucose are aH associated with increased 
Brisk for development of GDM. Our findings, therefore suggest that development of a 
routine AF screening protocol for aH Canadian mothers could be useful in detennining 
whether an in utero environment is characteristic of a pregnancy that is at high risk for 
developing into a GDM one or not; and do es so 10 weeks prior to current screening and 
diagnostic proto cols thus aHowing for earlier intervention and treatment. 
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Appendix B 
Consent F onns 
88 
';McGill 
School of Dietetics and 
Human Nutrition 
Facultv of Agrlcultural 
and Environmental Sciences 
McGili University 
Macdonald Campus 
~cole de diététique et 
nutrition humaine' 
Faculté de8 8clence8 de 
l'agriculture et de l'environnement 
Université McGiII 
Campus Macdonald 
Questionnaire 
Te!.: (514) 398-7842 
Fax: (514) 398-7739 
Website: http://www.agrenv.mcgill.ca/o 
21,111 Lakeshore 
Ste-Anne-de-Bellevue 
Québec, Canada H9X 3V9 
Please answer this brie! questionnaire. fou are reminded that al! the information provided will be kept strictly confide11 
Name: ________ ~ ______ _ Telephone number:. __________ _ 
Date ofbirth: _________ _ 
Ethnic background: North American 
European 
Middle Eastern 
Other 
Number of children 1 have already given birth to: __ 
Height: __ feet __ inches or 
South American 
African 
Asian 
The following information pertains to this pregnancy only: 
Weight prior to pregnancy: ___ pounds or ___ kg 
meters 
1 am in my __ th week of pregnancy Due date: ____________ _ 
Hospital where 1 will deliver: Royal Victoria 
Lakeshore General 
Jewish General 
St. Mary's 
Other 
Name of ObstetricianlGynecologist. _______________ _ 
1 am a smoker: Yes 
if Yes, while pregnant 1 smoke __ cigarettes 1 day 
Yes, but stopped while pregnant __ " 
No 
While pregnant, 1 consume an average of: 0-1 alcoholic drinks / week 
2-5 alcoholic drinks / week 
6-10 alcoholic drinks / week 
11-15 alcoholic drinks / week 
0-1 cups of coffee/tea 1 week __ 
2-5 cups of coffee/tea / week __ 
6-10 cups of coffee/tea / week __ 
11-15 cups of coffee/tea ; week __ 
1 am cUlTentl)' taking medication (prescribed by 111y doctor or over-the-counter): Yes_ No_ 
[(1'011 checkedyes. please specify ____ _ 
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